189 related articles for article (PubMed ID: 31777993)
1. RPV-modified epirubicin and dioscin co-delivery liposomes suppress non-small cell lung cancer growth by limiting nutrition supply.
Kong L; Cai FY; Yao XM; Jing M; Fu M; Liu JJ; He SY; Zhang L; Liu XZ; Ju RJ; Li XT
Cancer Sci; 2020 Feb; 111(2):621-636. PubMed ID: 31777993
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of tumor metastasis by targeted daunorubicin and dioscin codelivery liposomes modified with PFV for the treatment of non-small-cell lung cancer.
Wang Y; Fu M; Liu J; Yang Y; Yu Y; Li J; Pan W; Fan L; Li G; Li X; Wang X
Int J Nanomedicine; 2019; 14():4071-4090. PubMed ID: 31239668
[No Abstract] [Full Text] [Related]
3. Development of R
Liu JJ; Tang W; Fu M; Gong XQ; Kong L; Yao XM; Jing M; Cai FY; Li XT; Ju RJ
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):1947-1960. PubMed ID: 31079495
[TBL] [Abstract][Full Text] [Related]
4. Tumor Microenvironmental Responsive Liposomes Simultaneously Encapsulating Biological and Chemotherapeutic Drugs for Enhancing Antitumor Efficacy of NSCLC.
Kong L; Zhang SM; Chu JH; Liu XZ; Zhang L; He SY; Yang SM; Ju RJ; Li XT
Int J Nanomedicine; 2020; 15():6451-6468. PubMed ID: 32922011
[TBL] [Abstract][Full Text] [Related]
5. Application of multifunctional targeting epirubicin liposomes in the treatment of non-small-cell lung cancer.
Song XL; Ju RJ; Xiao Y; Wang X; Liu S; Fu M; Liu JJ; Gu LY; Li XT; Cheng L
Int J Nanomedicine; 2017; 12():7433-7451. PubMed ID: 29066893
[TBL] [Abstract][Full Text] [Related]
6. Enhanced antitumor efficacy using epirubicin and schisandrin B co-delivery liposomes modified with PFV via inhibiting tumor metastasis.
Jing M; Bi XJ; Yao XM; Cai F; Liu JJ; Fu M; Kong L; Liu XZ; Zhang L; He SY; Jia LQ; Li XT
Drug Dev Ind Pharm; 2020 Apr; 46(4):621-634. PubMed ID: 32162988
[TBL] [Abstract][Full Text] [Related]
7. Liposomes, modified with PTD(HIV-1) peptide, containing epirubicin and celecoxib, to target vasculogenic mimicry channels in invasive breast cancer.
Ju RJ; Li XT; Shi JF; Li XY; Sun MG; Zeng F; Zhou J; Liu L; Zhang CX; Zhao WY; Lu WL
Biomaterials; 2014 Aug; 35(26):7610-21. PubMed ID: 24912818
[TBL] [Abstract][Full Text] [Related]
8. The anti-ovarian cancer effect of RPV modified paclitaxel plus schisandra B liposomes in SK-OV-3 cells and tumor-bearing mice.
Zhang L; Kong L; He SY; Liu XZ; Liu Y; Zang J; Ju RJ; Li XT
Life Sci; 2021 Nov; 285():120013. PubMed ID: 34614418
[TBL] [Abstract][Full Text] [Related]
9. Targeting Epirubicin Plus Quinacrine Liposomes Modified with DSPE-PEG2000-C(RGDfK) Conjugate for Eliminating Invasive Breast Cancer.
Sun MG; Shi JF; Li XY; Zhao Y; Ju RJ; Mu LM; Yan Y; Li XT; Zeng F; Lu WL
J Biomed Nanotechnol; 2015 Aug; 11(8):1339-53. PubMed ID: 26295137
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of epi-1 modified epirubicin and curcumin encapsulated liposomes targeting-EpCAM in the inhibition of epithelial ovarian cancer cells.
Wang YJ; Tang L; Lu XH; Liu JT; Wang YY; Geng HX; Li XT; An Q
J Liposome Res; 2023 Jun; 33(2):197-213. PubMed ID: 36440599
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of EZH2 via activation of SAPK/JNK and reduction of p65 and DNMT1 as a novel mechanism in inhibition of human lung cancer cells by polyphyllin I.
Li L; Wu J; Zheng F; Tang Q; Wu W; Hann SS
J Exp Clin Cancer Res; 2016 Jul; 35(1):112. PubMed ID: 27421653
[TBL] [Abstract][Full Text] [Related]
12. Destruction of vasculogenic mimicry channels by targeting epirubicin plus celecoxib liposomes in treatment of brain glioma.
Ju RJ; Zeng F; Liu L; Mu LM; Xie HJ; Zhao Y; Yan Y; Wu JS; Hu YJ; Lu WL
Int J Nanomedicine; 2016; 11():1131-46. PubMed ID: 27042063
[TBL] [Abstract][Full Text] [Related]
13. ZLDI-8 suppresses angiogenesis and vasculogenic mimicry in drug-resistant NSCLC in vitro and in vivo.
Lu H; Wu C; Jiang XW; Zhao Q
Lung Cancer; 2023 Aug; 182():107279. PubMed ID: 37364397
[TBL] [Abstract][Full Text] [Related]
14. Mechanistic and therapeutic study of novel anti-tumor function of natural compound imperialine for treating non-small cell lung cancer.
Lin Q; Qu M; Patra HK; He S; Wang L; Hu X; Xiao L; Fu Y; Gong T; He Q; Zhang L; Sun X; Zhang Z
J Ethnopharmacol; 2020 Jan; 247():112283. PubMed ID: 31605736
[TBL] [Abstract][Full Text] [Related]
15. Small-molecule BH3 mimetic and pan-Bcl-2 inhibitor AT-101 enhances the antitumor efficacy of cisplatin through inhibition of APE1 repair and redox activity in non-small-cell lung cancer.
Ren T; Shan J; Li M; Qing Y; Qian C; Wang G; Li Q; Lu G; Li C; Peng Y; Luo H; Zhang S; Yang Y; Cheng Y; Wang D; Zhou SF
Drug Des Devel Ther; 2015; 9():2887-910. PubMed ID: 26089640
[TBL] [Abstract][Full Text] [Related]
16. Co-delivery of VEGF siRNA and Etoposide for Enhanced Anti-angiogenesis and Anti-proliferation Effect
Li F; Wang Y; Chen WL; Wang DD; Zhou YJ; You BG; Liu Y; Qu CX; Yang SD; Chen MT; Zhang XN
Theranostics; 2019; 9(20):5886-5898. PubMed ID: 31534526
[TBL] [Abstract][Full Text] [Related]
17. Multi-targeting NGR-modified liposomes recognizing glioma tumor cells and vasculogenic mimicry for improving anti-glioma therapy.
Huang D; Zhang S; Zhong T; Ren W; Yao X; Guo Y; Duan XC; Yin YF; Zhang SS; Zhang X
Oncotarget; 2016 Jul; 7(28):43616-43628. PubMed ID: 27283987
[TBL] [Abstract][Full Text] [Related]
18. Effects of polyphyllin I on growth inhibition of human non-small lung cancer cells and in xenograft.
Kong M; Fan J; Dong A; Cheng H; Xu R
Acta Biochim Biophys Sin (Shanghai); 2010 Nov; 42(11):827-33. PubMed ID: 20978038
[TBL] [Abstract][Full Text] [Related]
19. An-te-xiao capsule inhibits tumor growth in non-small cell lung cancer by targeting angiogenesis.
Han L; Wang JN; Cao XQ; Sun CX; Du X
Biomed Pharmacother; 2018 Dec; 108():941-951. PubMed ID: 30372906
[TBL] [Abstract][Full Text] [Related]
20. Dioscin suppresses TGF-β1-induced epithelial-mesenchymal transition and suppresses A549 lung cancer migration and invasion.
Lim WC; Kim H; Kim YJ; Choi KC; Lee IH; Lee KH; Kim MK; Ko H
Bioorg Med Chem Lett; 2017 Aug; 27(15):3342-3348. PubMed ID: 28610976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]